T
Tai-Tsang Chen
Researcher at Bristol-Myers Squibb
Publications - 33
Citations - 9099
Tai-Tsang Chen is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Ipilimumab & Randomized controlled trial. The author has an hindex of 19, co-authored 28 publications receiving 8183 citations. Previous affiliations of Tai-Tsang Chen include Columbia University.
Papers
More filters
Journal ArticleDOI
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert,Luc Thomas,Igor Bondarenko,Steven J. O'Day,Jeffrey S. Weber,Claus Garbe,Céleste Lebbé,Jean Francois Baurain,Alessandro Testori,Jean-Jacques Grob,Neville Davidson,Jon M. Richards,Michele Maio,Axel Hauschild,Wilson H. Miller,Pere Gascón,Michal Lotem,Kaan Harmankaya,Ramy Ibrahim,Stephen Francis,Tai-Tsang Chen,R. Humphrey,Axel Hoos,Jedd D. Wolchok +23 more
TL;DR: Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dACarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma.
Journal ArticleDOI
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf,F. Stephen Hodi,Caroline Robert,Jeffrey S. Weber,Kim Margolin,Omid Hamid,Debra A. Patt,Tai-Tsang Chen,David Berman,Jedd D. Wolchok +9 more
TL;DR: A plateau in the survival curve was observed, beginning at approximately 3 years, which was independent of prior therapy or ipilimumab dose, and added to the evidence supporting the durability of long-term survival in ipILimumab-treated patients with advanced melanoma.
Journal ArticleDOI
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
Moshe Talpaz,Neil P. Shah,Hagop M. Kantarjian,Nicholas J. Donato,John Nicoll,Ron Paquette,Jorge E. Cortes,Susan O'Brien,Claude Nicaise,Eric Bleickardt,M. Anne Blackwood-Chirchir,Vishwanath Iyer,Tai-Tsang Chen,Fei Huang,Arthur P. DeCillis,Charles L. Sawyers,Charles L. Sawyers +16 more
TL;DR: Dasatinib induces hematologic and cytogenetic responses in patients with CML or Ph-positive ALL who cannot tolerate or are resistant to imatinib, which is effective in Philadelphia chromosome-positive leukemias but relapse occurs.
Journal ArticleDOI
Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
Michele Maio,Jean-Jacques Grob,Steinar Aamdal,Igor Bondarenko,Caroline Robert,Luc Thomas,Claus Garbe,Vanna Chiarion-Sileni,Alessandro Testori,Tai-Tsang Chen,Marina Tschaika,Jedd D. Wolchok +11 more
TL;DR: The additional survival benefit of ipilimumab plus dacarbazine is maintained with twice as many patients alive at 5 years compared with those who initially received placebo plus dACarbazine.
Journal ArticleDOI
Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
TL;DR: Higher doses of ipilimumab produce greater Cminss that may be associated with increased tumor responses, longer survival, and higher rates of irAEs.